Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis

Company Overview

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Key Stats

• Today's Range: $6.15 to $6.32
• 50-Day Range: $6.16 to $8.33
• 52-Week Range: $6.08 to $16.76
• Volume: 1.05 million shs
• Average Volume: 1.11 million shs
• Market Capitalization: $635.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.57
• Consensus Rating: Buy

Day One Biopharmaceuticals Stock Analysis - MarketRank™

Day One Biopharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 459th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Day One Biopharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Day One Biopharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Day One Biopharmaceuticals are expected to decrease in the coming year, from ($0.72) to ($0.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Day One Biopharmaceuticals is -6.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Day One Biopharmaceuticals is -6.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Day One Biopharmaceuticals has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.83% of the float of Day One Biopharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Day One Biopharmaceuticals has a short interest ratio ("days to cover") of 14, which indicates bearish sentiment.

Change versus previous month

Short interest in Day One Biopharmaceuticals has recently decreased by 2.75%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Day One Biopharmaceuticals does not currently pay a dividend.

Dividend Growth

Day One Biopharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

23.83% of the float of Day One Biopharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Day One Biopharmaceuticals has a short interest ratio ("days to cover") of 14, which indicates bearish sentiment.

Change versus previous month

Short interest in Day One Biopharmaceuticals has recently decreased by 2.75%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.74

News Sentiment

Day One Biopharmaceuticals has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Day One Biopharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

7 people have searched for DAWN on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $167,298.00 in company stock.

Percentage Held by Insiders

Only 6.20% of the stock of Day One Biopharmaceuticals is held by insiders.

Percentage Held by Institutions

87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DAWN Stock Analysis - Frequently Asked Questions

How have DAWN shares performed this year?

Day One Biopharmaceuticals' stock was trading at $12.67 at the beginning of 2025. Since then, DAWN stock has decreased by 50.5% and is now trading at $6.27.
View the best growth stocks for 2025 here.

How were Day One Biopharmaceuticals' earnings last quarter?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) released its earnings results on Tuesday, May, 6th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.11. The firm earned $30.76 million during the quarter, compared to analysts' expectations of $30.28 million.
Read the conference call transcript.

When did Day One Biopharmaceuticals IPO?

Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Day One Biopharmaceuticals' major shareholders?

Top institutional investors of Day One Biopharmaceuticals include Vanguard Group Inc. (5.86%), Alyeska Investment Group L.P. (4.01%), Braidwell LP (3.49%) and Estuary Capital Management LP (3.28%). Insiders that own company stock include Ai Day1 Llc, Xi LP Canaan, Samuel C Blackman, Michael Gladstone, Papanek Julie Grant, Julie Papanek Grant, Charles N York II, Jeremy Bender, Adam Dubow, Saira Ramasastry and Lauren Merendino.
View institutional ownership trends.

How do I buy shares of Day One Biopharmaceuticals?

Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Day One Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Day One Biopharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 5/24/2025
• Next Earnings (Estimated): 7/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DAWN
• CIK: 1845337
• Web: dayonebio.com
• Phone: 650-484-0899
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $30.57
• High Stock Price Target: $40.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +387.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-188,920,000.00
• Net Margins: N/A
• Pretax Margin: -82.02%
• Return on Equity: -22.40%
• Return on Assets: -19.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.62
• Quick Ratio: 14.55

Sales & Book Value

• Annual Sales: $161.92 million
• Price / Sales: 3.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.98 per share
• Price / Book: 1.58

Miscellaneous

• Outstanding Shares: 101,362,000
• Free Float: 92,375,000
• Market Cap: $635.54 million
• Optionable: Optionable
• Beta: -1.24